Phase 2 Readout~quarter

Phase 2 Readout: haduvio

December 31, 2027

Company: Trevi Therapeutics, Inc. (TRVI)
Drug: haduvio
Indication: non-IPF interstitial lung disease ("non-IPF ILD")-related chronic cough

Other upcoming events for TRVI

Phase 2 ReadoutPhase 2 Readout: haduvio

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 2 Readout: haduvio — TRVI Phase 2 Readout | BioSniper